By further comparing the differences between antagonist and knockout models, it was evident that CCL2/CCR2 antagonists did not improve splenomegaly, lymphadenopathy, and circulating total/autoantibodies, suggesting the local involvement of CCL2/CCR2 in autoimmune target tissues, such as the kidney [56, 58, 59]. This evidence concerns the gene CCR2 and Splenomegaly.